pharma · Symptomatic hypertrophic cardiomyopathy (HCM) · SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Cytokinetics
Cytokinetics (Ireland) Limited
Cytokinetics (Ireland) is a pharma organization headquartered in GB. Primary therapeutic focus areas include Symptomatic hypertrophic cardiomyopathy (HCM), SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, Heart Failu
South San Francisco, USA HQ
1998 Founded
759 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 1998
- Employees
- 759
- Programs
- 5
- Drugs
- 7
- Patents
- 0
CY 6022
Phase 2 · small molecule · Symptomatic hypertrophic cardiomyopathy (HCM)
CY 6022 for Symptomatic hypertrophic cardiomyopathy (HCM) is a Phase 2 program (small_molecule) at Cytokinetics (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Internal code CY 6022
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cytokinetics (Ireland) Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Symptomatic hypertrophic cardiomyopathy (HCM)
- Status
- active
- Trials
- 1